Chengyin Min - Dept Biochem, Boston Univ

基本信息

浏览量：22

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 34 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

CTLA4 Blockade Abrogates KEAP1/STK11-related Resistance to PD-(L)1 Inhibitors

Ferdinandos Skoulidis,Haniel A. Araujo,Minh Truong Do,Yu Qian, Xin Sun,Ana Galan Cobo, John T. Le,Meagan Montesion,Rachael Palmer,Nadine Jahchan,Joseph M. Juan,Chengyin Min,

NATURE (2024)

引用0浏览0WOSNATURE引用

LIG1 Inactivation Selectively Inhibits Growth of BRCA1 Mutant Cells in Vitro and in Vivo

Lauren Martires,Leanne G. Ahronian,Charlotte Pratt,Nikitha Das, Xiaobin Zhang,Douglas A. Whittington,Hongxiang Zhang, Binzhang Shen,Jon Come,Patrick McCarren,Mu-Sen Liu,Chengyin Min,

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Abstract 3363: LIG1 Inactivation Selectively Inhibits Growth of BRCA1 Mutant Cells in Vitro and in Vivo

Lauren Martires,Leanne G. Ahronian,Charlotte Pratt,Nikitha Das,Xiaobin Zhang,Douglas A. Whittington,Hongxiang Zhang,Binzhang Shen,Jon Come,Patrick McCarren,Mu-Sen Liu,Chengyin Min,

Cancer Researchno. 6_Supplement (2024): 3363-3363

引用0浏览0引用

792 TNG917: a Potent and Orally Active Inhibitor of Euchromatic Histone Lysine Methyltransferases (EHMT1/2) for the Treatment of Immune-Cold Tumors

Alvin Lu,Brian Haines, Wenhai Zhang, Minjie Zhang,Douglas A Whittington, Maria Lucia Dam Ferdinez,Yi Yu,Samuel R Meier,Ashley Choi,Alborz Bejnood,Madhavi Bandi,Katherine Lazarides,

Regular and Young Investigator Award Abstracts (2024)

引用0浏览0引用

TNG917 is a Clinical-Grade, Potent and Selective Inhibitor of EHMT1/2 for the Treatment of Immune Cold Tumors

Alvin Lu,Brian Haines, Ji Lei, Wenhai Zhang, Minjie Zhang,Douglas A. Whittington, Maria Lucia Ferdinez,Yi Yu,Samuel R. Meier,Ashley Choi,Alborz Bejnood,Madhavi Bandi,

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Abstract 3242: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors

Alvin Lu,Brian Haines, Ji Lei,Wenhai Zhang,Minjie Zhang,Douglas A. Whittington, Maria Lucia Ferdinez,Yi Yu,Samuel R. Meier,Ashley Choi,Alborz Bejnood,Madhavi Bandi,

Cancer Researchno. 6_Supplement (2024): 3242-3242

引用0浏览0引用

Data from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer

Chengyin Min,Ziyang Yu,Kathrin H. Kirsch,Yingshe Zhao,Siddharth R. Vora,Philip C. Trackman,Douglas B. Spicer,Lynn Rosenberg,Julie R. Palmer,Gail E. Sonenshein

crossref（2023）

引用0浏览0引用

870 CoREST Inhibition by TNG260 Increases Expression of Immunomodulatory Genes in STK11-mutant Cancer and Sensitizes to Immune Checkpoint Blockade

Alan Huang,Andre Mignault,Minjie Zhang,Yi Yu,Leanne Ahronian, Xinyuan Wu,Chengyin Min,Alborz Bejnood,Nikitha Das,Preksha Shahagadkar,Alice W Tsai,Lauren Flynn,

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

Abstract ND12: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers

Leanne G. Ahronian,Minjie Zhang,Chengyin Min,Alice Tsai,Jacques Ermolieff,Patrick McCarren, Margaret Wyman, David Guerin, Ye Wang,Alborz Bejnood, Kenjie Amemiya,Brian McMillan,

Cancer Researchno. 7_Supplement (2023): ND12-ND12

引用0浏览0引用

Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer

Chengyin Min,Ziyang Yu,Kathrin H. Kirsch,Yingshe Zhao,Siddharth R. Vora,Philip C. Trackman,Douglas B. Spicer,Lynn Rosenberg,Julie R. Palmer,Gail E. Sonenshein

crossref（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn